Cue Biopharma, Inc.
CUE
$0.768
-$0.0004-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.83% | 14.03% | 9.42% | 3.65% | 4.30% |
| Total Depreciation and Amortization | -31.61% | 115.16% | 20.01% | 99.88% | 90.25% |
| Total Amortization of Deferred Charges | 0.00% | -2.63% | 0.00% | 0.00% | 19.35% |
| Total Other Non-Cash Items | -16.40% | -19.09% | 4.45% | -3.21% | -8.63% |
| Change in Net Operating Assets | -427.30% | -460.69% | -221.78% | -268.63% | -362.36% |
| Cash from Operations | 9.09% | 3.18% | 0.15% | 5.25% | 4.41% |
| Capital Expenditure | -- | -6,300.00% | 17.72% | 61.81% | -- |
| Sale of Property, Plant, and Equipment | 4,800.00% | 4,750.00% | -100.00% | -100.00% | -66.67% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 212.49% | 205.88% | 202.27% |
| Cash from Investing | -99.87% | -99.89% | 209.21% | 203.80% | 201.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -99.95% | -300.00% | -- | -- | -- |
| Issuance of Common Stock | 2.76% | -35.16% | -41.55% | -50.80% | -64.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -13.63% | -53.72% | -64.11% | -64.45% | -77.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -740.72% | -189.20% | -72.94% | -28.79% | 75.71% |